10% Shareholder Casdin Partners Files New $15.6M Stock Sale Intent
BLFS sits 39% above its 52-week low of $17.86 on elevated volume (2.3× avg).
Summary
A 10% shareholder, Casdin Partners, has filed a new Form 144 to sell $15.6 million in BioLife Solutions stock, continuing a pattern of significant dispositions.
Key Events · Ownership and Investor Activity · BLFS
-
Major Shareholder Intent to Sell
Casdin Partners, a 10% shareholder, intends to sell 650,000 shares of common stock, valued at approximately $15.6 million, on or after May 21, 2026.
-
Continuation of Recent Sales
This filing follows previous Form 144s from Casdin Partners, which reported sales of 550,000 shares for $12.72 million over the past three months, including sales on May 19th and May 20th.
-
Significant Stake Reduction
The proposed sale represents approximately 1.33% of the company's outstanding shares, indicating a continued reduction in holdings by a major institutional investor.
Analysis · BLFS · Industrial Applications And Services
Casdin Partners, a major institutional investor and 10% shareholder, has filed a new Form 144 indicating its intent to sell an additional $15.6 million worth of BioLife Solutions common stock. This follows previous Form 144 filings from Casdin Partners, which reported sales of $12.72 million over the past three months, including sales on May 19th and May 20th. The continued significant selling pressure from a major institutional holder could weigh on investor sentiment, despite the company's recent positive financial results.
At the time of this filing, BLFS was trading at $24.74 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $17.86 to $29.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.